GlassScriptPhysician profile
Kyle A Cook
NPI 1831744457
$2,318.92
in general payments reported to CMS, 2019-2025
25 companies · $1,037 in 2025
The $1,037 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.05 · 2022: $13.51 · 2023: $262 · 2024: $994 · 2025: $1,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,293.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $333.23 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $233.68 | 2023-2025 | Airsupra, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $228.21 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $221.80 | 2023-2025 | Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.20 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $163.72 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Otsuka America Pharmaceutical, INC. | $125.92 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $99.26 | 2022-2025 | |
| Abbvie INC. | $92.96 | 2023-2025 | |
| Antares Pharma, INC. | $91.49 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Pfizer INC. | $69.26 | 2024-2025 | |
| Exact Sciences Corporation | $65.39 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $56.52 | 2024-2025 | General - Pain Management |
| Phathom Pharmaceuticals, INC. | $45.41 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $42.39 | 2025 | Zoryve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $38.58 | 2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $38.12 | 2025 | Fanapt |
| Collegium Pharmaceutical, INC. | $37.48 | 2025 | Belbuca |
| Lundbeck LLC | $30.33 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $24.27 | 2023 | Trintellix |
| Amgen INC. | $24.13 | 2024 | Repatha, Otezla |
| Axsome Therapeutics, INC. | $21.64 | 2025 | Auvelity |
| Hikma Pharmaceuticals USA | $17.32 | 2024 | Ryaltris |
| Alkermes, INC. | $13.56 | 2023 | Vivitrol |
| Becton, Dickinson and Company | $12.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.